Real-World Experience with COVID-19, Including Direct COVID-19 Antigen Testing and Monoclonal-Antibody Bamlanivimab in a Rural Critical Access Hospital in South Dakota
Copyright© South Dakota State Medical Association..
This article summarizes the experiences of COVID-19 patients diagnosed and treated at Faulkton Area Medical Center (FAMC), a rural critical access facility in South Dakota, during three periods of COVID-19. Retrospective chart review was used to classify COVID-19 patients into three groups by time frame: 1.Early March 2020, with the arrival of COVID-19 to South Dakota, until August 31, 2020; 2.September 1, 2020, with the use of rapid result direct COVID-19 virus antigen testing, through November 24,2020 (which took place during our COVID-19 surge); and 3.November 25, 2020, the start of bamlanivimab infusions on high-risk patients with COVID-19, throughFebruary15, 2021, the cutoff for this review. Faulk County had higher COVID-19 case rates and COVID-19 death rates than South Dakota in general. Final review of the data showed stable overall hospitalization rates at FAMC in each of these time periods. Data was broken down by age and not other demographics due to small patient population size and limited ability to blind data. Breakdown of the data showed the hospitalization rates in the 60-90+ age groups did decrease from 33.3 percent to 22.2 percent, following bamlanivimab use. Absolute risk reduction 11.1 percent. Relative risk reduction of hospitalization from November 25, 2020 through February 15, 2021 compared to September 1, 2020 through November 25, 2020 was 0.33. (odds ratio = 0.57) (CI (95 percent) 0.21-1.58). This is not statistically significant. NNT=9. Data is limited by small overall numbers of patients and lack of data in Faulkton area residents who sought medical care outside the local facility.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
South Dakota medicine : the journal of the South Dakota State Medical Association - 74(2021), 11 vom: 18. Nov., Seite 513-518 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Anderson, Sylvia [VerfasserIn] |
|---|
| Themen: |
45I6OFJ8QH |
|---|
| Anmerkungen: |
Date Completed 12.01.2022 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM335432913 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335432913 | ||
| 003 | DE-627 | ||
| 005 | 20231225225833.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335432913 | ||
| 035 | |a (NLM)35008137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Anderson, Sylvia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-World Experience with COVID-19, Including Direct COVID-19 Antigen Testing and Monoclonal-Antibody Bamlanivimab in a Rural Critical Access Hospital in South Dakota |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© South Dakota State Medical Association. | ||
| 520 | |a This article summarizes the experiences of COVID-19 patients diagnosed and treated at Faulkton Area Medical Center (FAMC), a rural critical access facility in South Dakota, during three periods of COVID-19. Retrospective chart review was used to classify COVID-19 patients into three groups by time frame: 1.Early March 2020, with the arrival of COVID-19 to South Dakota, until August 31, 2020; 2.September 1, 2020, with the use of rapid result direct COVID-19 virus antigen testing, through November 24,2020 (which took place during our COVID-19 surge); and 3.November 25, 2020, the start of bamlanivimab infusions on high-risk patients with COVID-19, throughFebruary15, 2021, the cutoff for this review. Faulk County had higher COVID-19 case rates and COVID-19 death rates than South Dakota in general. Final review of the data showed stable overall hospitalization rates at FAMC in each of these time periods. Data was broken down by age and not other demographics due to small patient population size and limited ability to blind data. Breakdown of the data showed the hospitalization rates in the 60-90+ age groups did decrease from 33.3 percent to 22.2 percent, following bamlanivimab use. Absolute risk reduction 11.1 percent. Relative risk reduction of hospitalization from November 25, 2020 through February 15, 2021 compared to September 1, 2020 through November 25, 2020 was 0.33. (odds ratio = 0.57) (CI (95 percent) 0.21-1.58). This is not statistically significant. NNT=9. Data is limited by small overall numbers of patients and lack of data in Faulkton area residents who sought medical care outside the local facility | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 650 | 7 | |a bamlanivimab |2 NLM | |
| 650 | 7 | |a 45I6OFJ8QH |2 NLM | |
| 700 | 1 | |a Baloun, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Loewen, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Poeppel, Lindsey |e verfasserin |4 aut | |
| 700 | 1 | |a Schweitzer, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Winther, Paula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t South Dakota medicine : the journal of the South Dakota State Medical Association |d 2006 |g 74(2021), 11 vom: 18. Nov., Seite 513-518 |w (DE-627)NLM161106110 |x 0038-3317 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2021 |g number:11 |g day:18 |g month:11 |g pages:513-518 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2021 |e 11 |b 18 |c 11 |h 513-518 | ||